


# PRODUCT INFORMATION



## AAA

Item No. 32733

**Formal Name:** (20-hydroxyicosa-6Z,15Z-dienoyl) aspartate, disodium salt  
**MF:** C<sub>24</sub>H<sub>39</sub>NO<sub>6</sub> • 2Na  
**FW:** 483.5  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

AAA is supplied as a crystalline solid. A stock solution may be made by dissolving the AAA in the solvent of choice, which should be purged with an inert gas. AAA is slightly soluble in DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of AAA can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of AAA in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

## Description

AAA is an antagonist of G protein-coupled receptor 75 (GPR75).<sup>2</sup> It increases basal GPR75 protein levels and inhibits 20-HETE-induced reductions in GPR75 protein levels in PC3 cells. AAA (5 and 10 μM) also reduces 20-HETE-induced phosphorylation of EGFR, NF-κB, and Akt in, and cell migration of, PC3 cells. *In vivo*, AAA (10 mg/kg per day) reduces systolic blood pressure, albuminuria, renal angiotensin II levels, and cardiac hypertrophy in a Cyp1a1-Ren-2 transgenic rat model of malignant hypertension when administered prior to induction or after establishment of hypertension.<sup>1</sup>

## References

1. Sedláková, L., Kikerlová, S., Husková, Z., *et al.* 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: A study in Cyp1a1-Ren-2 transgenic rats. *Biosci. Rep.* **38(5)**, BSR20171496 (2018).
2. Cárdenas, S., Colombero, C., Panelo, L., *et al.* GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1865(2)**, 158573 (2020).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/03/2021

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM